Author Archives: Diogo Pinto

Soleno Granted Patent Covering Potential Oral Treatment, DCCR, Now in Phase 3 Study in Patients

Soleno Therapeutics announced the awarding of a patent for diazoxide choline controlled-release (DCCR) tablets, the company’s investigational therapy for Prader-Willi syndrome (PWS) being evaluated in a new Phase 3 trial. The patent covers “pharmaceutical formulations of diazoxide and diazoxide choline” to treat patients with poor lean body mass and a lean…

FDA Grants Fast Track Status to Soleno’s Investigational Therapy DCCR for PWS

Soleno Therapeutics recently received fast track status from the U.S. Food and Drug Administration for diazoxide choline controlled-release (DCCR), its investigational treatment for Prader-Willi syndrome (PWS). DCCR is an extended-release, salt formulation of diazoxide, taken as a once-daily tablet. Diazoxide is a potassium channel activator, capable of crossing…

Live Monitoring Allows Detection of Silent Aspiration in Prader-Willi Infants

Silent aspiration, a consequence of a swallowing dysfunction, was detected in infants with Prader-Willi syndrome (PWS) by fluorescent live video, a study found. The research was published in the journal Medicine (Baltimore) in a study titled, “Silent aspiration in infants with Prader-Willi syndrome identified by videofluoroscopic swallow study.”…